Are GlaxoSmithKline plc and Indivior plc the perfect pharma pairing?

Roland Head explains why GlaxoSmithKline plc (LON:GSK) and Indivior plc (LON:INDV) could work well together in your portfolio.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When faced with a choice between growth and income, what should you do? In the case of GlaxoSmithKline (LSE: GSK) and Indivior (LSE: INDV), the best answer might be to buy both.

GlaxoSmithKline’s appeal as a long-term income stock is no secret. Although the firm’s dividend-paying ability has been stretched over the last couple of years, the situation appears to be improving.

The company’s efforts to reduce debt and restructure its portfolio appear to be paying off. Recent first-quarter results showed an 8% rise in core profits compared to the same period last year. Glaxo was sufficiently confident in its full-year outlook to firm up its forecast for 2016. Core earnings are now expected to be 10-12% higher, on a constant exchange rate basis.

City analysts are convinced, for now at least. Earnings forecasts for the current year have been increased by 4.4% since January, while those for 2017 have also been notched higher.

Glaxo’s big appeal is its combination of a chunky dividend and the potential for long-term growth, as global pharmaceutical sales rise. The company’s guidance is for a dividend of 80p both this year and next. While this lack of growth hints that the firm’s payout may still be too generous, the forecast yield of 5.5% is very attractive. In my view a cut is relatively unlikely.

This stock could double

Glaxo may be an attractive income stock, but the firm’s £70bn market cap means that rapid capital gains are unlikely. Glaxo’s share price has risen by 24% over the last six years, almost exactly in line with the FTSE 100.

Investors looking for big gains may have to take a little more risk. One possibility is Indivior.

On the face of it, Reckitt Benckiser’s decision to spin off its pharma business into Indivior looks increasingly wise. Indivior’s profits are crumbling as the firm faces a rising tide of generic competition for its sole commercial product, Suboxone. Post-tax profits fell by 42% last year, despite sales only falling by 6%.

A decline on this scale isn’t sustainable, and if generic alternatives to the firm’s flagship Suboxone Film variant are approved, the situation could get much worse. Although Indivior does have some new products in its pipeline, commercialisation is still some distance away.

Why consider investing?

One key attraction is that Indivior has a fairly strong balance sheet. The firm had a cash balance of $543m at the end of the first quarter, with net debt of $83m. Indivior’s debt isn’t due for renewal until 2020.

In my opinion, Indivior’s management will be hoping to use its cash balance to help fund an acquisition or merger deal that will broaden the company’s portfolio. Another possibility is that Indivior will be acquired.

In any case, I expect the firm to attempt some kind of transformative transaction over the next couple of years. If successful, this could give the firm a much stronger long-term outlook. The current share price of 172p — giving a 2016 forecast P/E of 10 — may end up looking very cheap.

The risk is that Indivior’s management won’t pull off this trick. If this happens then profits and the share price could decline indefinitely.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Reckitt Benckiser. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »